Share:
MISSISSAUGA, Ontario, Dec. 15, 2020 (GLOBE NEWSWIRE) Microbix Biosystems Inc. (TSX:MBX, OTCQB:MBXBF, Microbix®)), a life sciences innovator and exporter, announces it has been invited to present about the performance of two types of its test-workflow Quality Assessment Products (QAPs™) at the 2020 virtual Scientific Meeting and Clinical Lab Expo of the American Association of Clinical Chemistry (AACC) taking place December 13-17, 2020.
The first abstract presentation is titled
Novel
Mycoplasma genitalium (Mgen) and AMR Mgen A2059G Materials for use in a Cross-Platform NAAT Quality Control. It reviews performance of novel, innovative, & proprietary REDx™ (IVD) Mgen positive controls, and PROCEEDx™ (RUO) Mgen A2059G positive samples.